세계의 알프롤릭스(Alprolix) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Alprolix is a recombinant coagulation factor IX Fc fusion protein designed to treat and prevent bleeding episodes in individuals with hemophilia B. It works by substituting the missing factor IX, promoting proper blood clotting, and has an extended half-life, which minimizes the need for frequent infusions to maintain effective treatment.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The alprolix market primarily consists of recombinant coagulation factor IX and plasma-derived coagulation factor IX. Recombinant factor IX is a bioengineered protein used to replace the deficient or dysfunctional factor IX in hemophilia B patients, helping to prevent excessive bleeding and support normal clotting. These products are available in different formulations, including injectable solutions and reconstitution powders. They are applied in treatments for hemophilia B, prophylaxis, and surgeries and are distributed through hospitals, specialty clinics, and online pharmacies.

The alprolix market research report is one of a series of new reports from The Business Research Company that provides alprolix market statistics, including alprolix industry global market size, regional shares, competitors with a alprolix market share, detailed alprolix market segments, market trends, and opportunities, and any further data you may need to thrive in the alprolix industry. This alprolix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alprolix market size is expected to see rapid growth in the next few years. It will grow to $1,911.2 million in 2029 at a compound annual growth rate (CAGR) of 10%. The growth in the forecast period can be attributed to personalized medicine, increasing adoption of extended half-life factor therapies, greater focus on improving treatment adherence and quality of life, expanding healthcare infrastructure in emerging markets, rising awareness about bleeding disorders. Major trends in the forecast period include collaborations between pharmaceutical companies and healthcare providers, product innovations, advancements in clotting factor therapies, improvements in patient care through extended half-life therapies.

The growing prevalence of hemophilia B is expected to drive the expansion of the alprolix market in the coming years. Hemophilia B, also known as Christmas disease, is a rare inherited bleeding disorder caused by a deficiency or absence of clotting factor IX. The rising incidence of hemophilia B is largely attributed to improvements in diagnostic techniques, increased awareness and reporting, better healthcare systems that enable earlier detection, and the longer life expectancy of individuals with hemophilia due to advancements in treatment options. Alprolix, a long-acting recombinant clotting factor IX, is beneficial for patients with hemophilia B as it reduces bleeding episodes and the frequency of infusions by offering extended protection through its prolonged half-life, ultimately improving patients' quality of life. For example, in October 2023, a report from the World Federation of Hemophilia (WFH) revealed that, as of 2022, there were 257,146 identified hemophilia patients worldwide, including 42,203 individuals with hemophilia B. As such, the increasing prevalence of hemophilia B is a key factor driving the alprolix market.

The alprolix market has seen notable progress in recent years, fueled by a focus on innovative therapies to address unmet medical needs in hemophilia B treatment. One of the promising developments is Factor IX gene therapy, which involves delivering a functional copy of the FIX gene using adeno-associated virus (AAV) vectors. This approach aims to provide long-term clotting factor production, reduce bleeding episodes, and potentially offer a one-time treatment for hemophilia B. For instance, in April 2024, Pfizer Inc. received approval from the U.S. FDA for Beqveztm (fidanacogene elaparvovec), a gene therapy designed to treat hemophilia B. This approval represents a significant breakthrough in hemophilia treatment, offering the potential for a one-time therapy that could eliminate or reduce the need for routine clotting factor infusions. The therapy works by delivering a functional copy of the recombinant clotting factor IX gene, which provides sustained levels of factor IX and helps prevent bleeding episodes. Clinical trials have demonstrated durable efficacy and a favorable safety profile for patients with severe or moderately severe hemophilia B.

In August 2024, Bora Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired Emergent BioSolutions for an undisclosed sum. This acquisition will allow Bora Pharma to expand its capabilities in the biotechnology and pharmaceutical sectors, particularly by enhancing its contract development and manufacturing services (CDMO) portfolio. Emergent BioSolutions, a U.S.-based company, is known for offering recombinant coagulation factor IX-based treatments.

Key player operating in the alprolix market is Sanofi

North America was the largest region in the alprolix market in 2024. The regions covered in alprolix report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alprolix market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alprolix market consists of sales of alprolix 250IU and alprolix 500 IU. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alprolix Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alprolix market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alprolix ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alprolix market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Recombinant Coagulation Factor IX; Plasma-Derived Coagulation Factor IX
• 2) By Formulation: Injectable Solution; Powder For Reconstitution
• 3) By Application: Hemophilia B Treatment; Prophylaxis; Surgery
• 4) By Distribution: Hospitals; Specialty Clinics; Online Pharmacies
• Companies Mentioned: Sanofi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alprolix Market Characteristics

3. Alprolix Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Alprolix Market Trends And Strategies

5. Alprolix Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Alprolix Growth Analysis And Strategic Analysis Framework

• 6.1. Global Alprolix PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Alprolix Market Growth Rate Analysis
• 6.4. Global Alprolix Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Alprolix Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Alprolix Total Addressable Market (TAM)

7. Global Alprolix Market Pricing Analysis & Forecasts

8. Alprolix Market Segmentation

• 8.1. Global Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Coagulation Factor IX
• Plasma-Derived Coagulation Factor IX
• 8.2. Global Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Solution
• Powder For Reconstitution
• 8.3. Global Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hemophilia B Treatment
• Prophylaxis
• Surgery
• 8.4. Global Alprolix Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinis
• Online Pharmacies

9. Global Alprolix Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Alprolix Market Regional And Country Analysis

• 10.1. Global Alprolix Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Alprolix Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Alprolix Market

• 11.1. Asia-Pacific Alprolix Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Alprolix Market

• 12.1. China Alprolix Market Overview
• 12.2. China Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Alprolix Market

• 13.1. India Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Alprolix Market

• 14.1. Japan Alprolix Market Overview
• 14.2. Japan Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Alprolix Market

• 15.1. Australia Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Alprolix Market

• 16.1. South Korea Alprolix Market Overview
• 16.2. South Korea Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Alprolix Market

• 17.1. Western Europe Alprolix Market Overview
• 17.2. Western Europe Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Alprolix Market

• 18.1. UK Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Alprolix Market

• 19.1. Germany Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Alprolix Market

• 20.1. France Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Alprolix Market

• 21.1. Eastern Europe Alprolix Market Overview
• 21.2. Eastern Europe Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Alprolix Market

• 22.1. North America Alprolix Market Overview
• 22.2. North America Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Alprolix Market

• 23.1. USA Alprolix Market Overview
• 23.2. USA Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Alprolix Market

• 24.1. Canada Alprolix Market Overview
• 24.2. Canada Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Alprolix Market

• 25.1. South America Alprolix Market Overview
• 25.2. South America Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Alprolix Market

• 26.1. Middle East Alprolix Market Overview
• 26.2. Middle East Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Alprolix Market

• 27.1. Africa Alprolix Market Overview
• 27.2. Africa Alprolix Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Alprolix Market, Segmentation By Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Alprolix Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Alprolix Market Competitive Landscape And Company Profiles

• 28.1. Alprolix Market Competitive Landscape
• 28.2. Alprolix Market Company Profiles
  • 28.2.1. Sanofi Overview, Products and Services, Strategy and Financial Analysis

29. Global Alprolix Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Alprolix Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Alprolix Market

32. Recent Developments In The Alprolix Market

33. Alprolix Market High Potential Countries, Segments and Strategies

• 33.1 Alprolix Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Alprolix Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Alprolix Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer